Madrigal CMO/President of R&D Rebecca Taub steps down, becomes Senior Advisor through Dec 2025

MADRIGAL PHARMACEUTICALS, INC.

Dr. Taub transitions from CMO and President of R&D to Senior Scientific and Medical Advisor effective April 21, 2025, through end of 2025.
She will continue to serve on Madrigal's Board of Directors.
Will receive base salary of $621,000 through Dec 31, 2025, and eligible for a 50% target bonus.
Entered a Severance and Change of Control Agreement with standard severance: 12-month salary continuation, equity acceleration, and health benefits.
No successor named; Taub will provide transition support and scientific guidance for MASH programs.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Rebecca Taub

Senior Scientific and Medical Advisor

MDGL · MADRIGAL PHARMACEUTICALS, INC.

Effective: 2025-04-21
Filed: April 17, 2025, 7:59 PM ET

Pursuant to the Letter Agreement, effective as of April 21, 2025, Dr. Taub will transition from her current role and responsibilities to a new role as a Senior Scientific and Medical Advisor to the Company through the end of 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Rebecca Taub changed role as Senior Scientific and Medical Advisor at MADRIGAL PHARMACEUTICALS, INC..

Action: transitioned
Role: Senior Scientific and Medical Advisor

Exact text from the filing

Pursuant to the Letter Agreement, effective as of April 21, 2025, Dr. Taub will transition from her current role and responsibilities to a new role as a Senior Scientific and Medical Advisor to the Company through the end of 2025.

View on SEC.gov

MADRIGAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-25-018242

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.